Physicians are uncertain about when to pursue intensive glucose control among older patients with diabetes.
I
ntensive glucose control (hemoglobin A 1c [HbA 1c ] level Ͻ7% [1] ) decreases the risk for multiple complications in patients with diabetes compared with moderate glucose control (HbA 1c level about 7.9%) (2) (3) (4) . The importance of intensive glucose control has led to public health efforts to improve the delivery of diabetes care (5) .
Despite its promise, the benefits of intensive glucose control remain uncertain for the heterogeneous population of older diabetic patients. This uncertainty, reflected in the wide variation in practice by clinical specialty (6, 7) and the different therapeutic recommendations from leaders in the field of diabetes (8 -10) , arises from a lack of clinical trial data evaluating the benefits of long-term intensive glucose control in older patients, especially those with substantial comorbid illnesses or functional impairments.
The first guideline to acknowledge the unique care considerations of older diabetic patients (11) recommended an individualized approach to diabetes care that multiple medical organizations have since endorsed (12) (13) (14) . A central concept introduced in that guideline is that providers should consider targeting glucose control levels on the basis of life expectancy. Patients whose life expectancy is less than 5 years are considered unlikely to benefit from intensive glucose control, whereas patients with longer life expectancy are thought to be good candidates for intensive glucose control.
Although these recommendations represent a conceptual advance in diabetes care, they have received little evaluation. Comorbid illness and functional status are well known determinants of life expectancy (15, 16) ; however, the extent to which these characteristics influence the expected benefits of intensive glucose control is unknown. In addition, there are concerns about using limited life expectancy as a sole means of determining glucose control. Many older patients with limited life expectancy may also have prolonged duration of diabetes, a clinical characteristic that may increase the expected benefits of intensive con-trol. How these competing characteristics might interact and influence decisions is unknown.
One approach for gaining insight into these questions is to use existing clinical evidence in decision analyses (17) (18) (19) . An advantage of decision analysis is that it allows examination of clinical questions for patients that might typically be excluded from clinical trials. Recent advances in prediction models in diabetes (20) and geriatrics (21) enable us to evaluate how comorbid illnesses and functional status may alter the expected benefits of intensive glucose control in older type 2 diabetic patients.
METHODS
This decision analysis is an integration of multiple prediction models from the fields of diabetes and geriatrics. We housed all prediction models in the structure of an existing model of diabetes complications, the National Institutes of Health Model (17, 22) . This Monte Carlo simulation model is framed by simultaneous progression of disease through individual diabetes-related complications and death (Figure 1) . Within a 1-year cycle, patients move from 1 disease state to another or stay in the current disease state until death or age 95 years. The model is run for 10 000 iterations for each specific model setting, such as population characteristics or glucose level, with each iteration representing a patient life. The model was constructed by using Microsoft Excel 2000 (Microsoft, Seattle, Washington) and @Risk 4.0 (Palisades, Newfield, New York).
In the following sections, we describe the individual prediction models, the population of interest, the comparison treatments, the outcomes of interest, and sensitivity analyses. For details, see the Appendix Table (available at www.annals.org).
Diabetes Complications
The diabetes complication models are derived from the UKPDS (United Kingdom Prospective Diabetes Study) results (3, 20, 23, 24) . The UKPDS study group developed prediction models for all major diabetes-related complications. These models have been internally validated and externally validated with cardiovascular trial data (25) . We could not use the UKPDS prediction model for endstage renal disease because this model does not include glucose control as a predictor. We instead modeled the development of microalbuminuria and proteinuria, which are linked to the intensity of glucose control (19, 26) . For
Context
Whether tight glucose control benefits elderly patients with type 2 diabetes is subject to debate because some studies show adverse outcomes with tight control.
Contribution
This computer model estimated the net benefits of treating to a hemoglobin A 1c level of 7% versus 7.9% among individuals 60 to 80 years of age with various life expectancies and suggests modest benefits of tight control, ranging from 51 to 116 additional quality-adjusted days. Benefits decreased as age increased and life expectancy decreased, supporting a relaxation of hemoglobin A 1c targets for elderly people with comorbid illness.
Caution
The mortality index that the investigators used to predict life expectancy in the model is not appropriate for predicting an individual patient's life expectancy. probabilities under moderate control, we used prediction models developed by using optimization procedures to fit observations from the UKPDS control group to a functional form used in the original National Institutes of Health model (27) (Appendix Table, available at www .annals.org). To determine the transition probabilities for intensive glucose control, we used a multiplier derived by comparing the overall UKPDS results for individual complications. We used probabilities from an observational study for the transition between proteinuria and end-stage renal disease (28) .
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Incorporating Functional Status and Comorbid Illness into Background Mortality
We used mortality rates from a 4-year mortality index developed from the Health and Retirement Study (21) , rather than mortality rates from life tables (17, 22, 29) . This index was developed and validated with a split-sample approach. The index has a total score of 26, and each comorbid illness or functional impairment contributes 1 to 2 points to the index score. To calculate background mortality rates for the general population, we subtracted cardiovascular mortality rates for the general population from the mortality rates associated with each index score (30) . We then multiplied these mortality rates by 2.75, as in a previous study (22) , to reflect the higher background mortality rates for patients with diabetes.
We included points for age group and sex in the baseline index score for each hypothetical subgroup. We then systematically increased the mortality index score by as much as 14 additional points. Apart from these changes, we retained the National Institutes of Health model assumptions about death from other specific causes (31) (32) (33) .
Population
We performed simulations for hypothetical patients 60 to 80 years of age who had type 2 diabetes and no history of diabetes-related complications. We assumed the patients to have the demographic and clinical characteristics of diabetic patients older than age 60 years, as described in the NHANES (National Health and Nutrition Examination Surveys) from 1999 to 2002 (34) .
Hypothetical cohorts were divided into 5-year age groups with a uniform age distribution, which correspond to major groupings of older diabetic patients. We also varied the duration of diabetes for such patients (new onset, 0 to 5 years, 5 to 10 years, and 10 to 15 years). We assumed that the population had the sex and ethnic distributions observed in NHANES. We did not assume any additional effect of race on complication rates because the major ethnic minority groups included in the UKPDS data do not completely correspond with those in the United States.
Comparison Treatments
We compared the projected health effects of moderate glucose control (HbA 1c level, 7.9%) and intensive glucose control (HbA 1c level, 7.0%) (11, 35) We assumed that patients maintained these glucose control levels throughout their lives. In sensitivity analyses, we also compared HbA 1c levels of 9.0% versus 7.9% and HbA 1c levels of 7.0% versus 6.5% (36) .
Other Treatment Assumptions
We held all other elements of care constant in the 2 scenarios (37-39). We selected cardiovascular risk factor levels for hypothetical patients from the age-, race-, and sex-specific subgroup distributions for systolic blood pressure, diastolic blood pressure, total cholesterol, highdensity lipoprotein cholesterol, and smoking for diabetic patients in NHANES (1999 -2002) .
Outcomes
Outcomes of interest included the lifetime incidence of individual complications and life expectancy. We report the benefits of intensive versus moderate glucose control as an average absolute risk reduction in complications and added days of life. The primary outcome of interest was the average difference in quality-adjusted days. To calculate quality-adjusted benefits, we used utility weights for major complications used in previous analyses (19, 27, 40 -44) . We assumed no disutility of life with different treatments (45) . When multiple health states occurred, we used the minimum health state method (46).
Sensitivity Analysis
The UKPDS prediction models assume that the glucose level is a modifiable risk factor for coronary heart disease in type 2 diabetes, when in fact this remains a highly debated and studied topic (47) . To assess the effect of this assumption, we replaced the UKPDS models for coronary heart disease and stroke with Framingham models (48, 49) . We also conducted sensitivity analyses on other important model assumptions, such as the background mortality rate inflator. We performed subgroup analyses for men, women, white persons, African-American persons, and Latino persons.
Role of the Funding Source
The National Institute on Aging, National Institute of Diabetes and Digestive and Kidney Diseases, Chicago Center of Excellence in Health Promotion Economics, and National Institute of Child Health and Human Development had no role in the design, conduct, or analysis of the study or in the decision to submit the manuscript for publication.
RESULTS
Base-Case Results
We predicted that cardiovascular complications would be the most frequent complication in all patient subgroups (44% to 54% lifetime incidence of coronary heart disease) (Table) . Microvascular complications had lower lifetime incidences that varied by starting age and duration of diabetes in the simulated patient. The incidence of end-stage renal disease and amputation decreased with increasing starting age but increased with increasing diabetes dura-tion. Conversely, incidence of blindness increased with increasing starting age but decreased with increasing diabetes duration, which reflects the inclusion of age at onset of diabetes as a predictor in the UKPDS blindness model.
Life expectancy decreased with increasing starting age and increasing duration of diabetes. Our life expectancy predictions for healthy older patients with new-onset diabetes matched expectations from epidemiologic studies of mortality and diabetes (50, 51) . Quality-adjusted life expectancy was 1 to 1.5 years less than unadjusted life expectancy.
The overall magnitude of expected benefits of achieving intensive glucose control compared with moderate glucose control decreased as the age of hypothetical patients increased (Table) . As the starting age of a simulated patient increased, the level of absolute risk reduction decreased for end-stage renal disease and amputation but remained stable for blindness and coronary heart disease. Life expectancy and quality-of-life benefits decreased with increasing age. The expected quality-adjusted benefit of intensive glucose control was 106 days (95% CI, 95 to 117 days) at 60 to 64 years of age and decreased to 52 days (CI, 46 to 58 days) at 75 to 79 years of age among individuals with no comorbid illness or functional impairment. Increasing the duration of diabetes increased the overall expected quality-of-life benefits of intensive glucose control. For patients age 60 to 64 years, the overall quality-of-life benefit increased from 106 days for new-onset diabetes to 114 days for durations of diabetes beyond 5 years.
In each age group, we observed larger differences in the expected benefits of intensive glucose control with changes in the mortality index score (Figure 2 and Appendix Figure 1 , available at www.annals.org). As the index score increased, life expectancy decreased. In patients 60 to 64 years of age who had new-onset diabetes, life expectancy decreased from 14.6 years (CI, 14.4 to 14.7 years) at baseline to 9.7 years (CI, 9.6 to 9.9 years) with 3 additional index points and to 4.8 years (CI, 4.7 to 4.9 years) with 7 additional index points. As life expectancy decreased, so did the expected benefits. Over the same interval of index points, life expectancy benefits decreased from 114 days (CI, 101 to 128 days) to 41 days (CI, 34 to 48 days) to 5 days (CI, 3 to 8 days) and quality-adjusted benefits decreased from 106 days (CI, 95 to 117 days) to 44 days (CI, 38 to 50 days) to 8 days (CI, 5 to 10 days).
We also observed a negative association among life expectancy, benefits, and mortality index score in patients with greater duration of diabetes. Again, life expectancy decreased with an increasing index score. For patients 60 to 64 years of age who had had diabetes for 10 to 15 years, life expectancy decreased from 13.5 years (CI, 13.3 to 13.6 years) at baseline to 8.0 years (CI, 7.9 to 8.1 years) with 4 additional index points and to 3.9 (CI, 3.8 to 4.0) with 8 additional index points. The expected benefits decreased over the same intervals from 116 quality-adjusted days (CI, 103 to 129 days) to 36 days (CI, 29 to 43 days) to 8 days (CI, 6 to 11 days) (Figure 2, D) .
When we examined these interrelationships by specific complications, we found distinct patterns for different complications (Figure 3 and Appendix Figure 2 , available at www.annals.org). For end-stage renal disease, absolute risk reduction decreased as the mortality index score increased, even among patients with extended duration of diabetes (Figure 3, B and D) . In contrast, the benefits of preventing amputation decreased but remained close to an absolute risk reduction of more than 0.5% at high index scores when duration of diabetes exceeded 5 years ( Figure  3 , B and D). These patterns reflect differences in the size of baseline incidence rates and in assumptions regarding how glucose control affected individual complication rates.
Sensitivity Analysis
When we used Framingham models, the predicted rates of cardiovascular disease were lower and life expectancies were higher than in the base-case analysis, but expected benefits of intensive glucose control were lower. For patients 60 to 64 years of age with new-onset diabetes and moderate glucose control, the incidence of coronary heart disease decreased from 52% to 37% (CI, 36% to 38%) and life expectancy increased from 14.6 years to 16.1 years (CI, 15.9 to 16.3 years). Despite longer life expectancy, the expected benefits of intensive control were less than half of those observed in the base case (44 quality-adjusted days [CI, 38 to 50 days] instead of 106 days) because of the absence of glucose control as a predictor in the Framingham models. Despite all of these changes, the basic relationship between the mortality index score and expected benefits observed earlier was maintained. Expected benefits for the same patients age 60 to 64 years decreased from 44 days (CI, 38 to 50 days) to 16 days (CI, 13 to 19 days) with 3 additional index points and to 3 days (CI, 2 to 4 days) with 7 additional index points.
The results of our other sensitivity analyses did not deviate significantly from those of the base-case analysis. When we assumed no inflation of the nondiabetic background mortality rate, life expectancies increased by 2 to 3 years and the magnitude of expected benefits increased (for example, from 106 quality-adjusted days to 126 days [CI, 115 to 137 days] for healthy patients age 60 to 64 years who had new-onset diabetes). Expected benefits continued to decrease with an increasing mortality index score, but at slightly higher index scores than in the base case. For example, in the same patients age 60 to 64 years, expected benefits were reduced to less than 20 quality-adjusted days with 10 additional index points instead of 7 index points. In subgroup analyses, we found small differences in these patterns between men and women: For patients age 60 to 64 years, benefits dropped below 20 quality-adjusted days for men at 5 additional index points, whereas women had this decrease at 7 additional index points.
Comparisons of different levels of glucose control altered the baseline magnitude of benefit of achieving lower glucose control targets but did not significantly alter the importance of the index score on the expected benefits. For healthy patients age 60 to 64 years with new-onset diabetes, the benefit was 131 quality-adjusted days in the comparison between HbA 1c levels of 9.0% and 7.9% and 52 days in the comparison between HbA 1c levels of 7.0% and 6.5%. The benefit in the first comparison declined to 10 quality-adjusted days with 7 additional index points. The benefit declined in the second comparison to 3 qualityadjusted days with 7 additional index points.
In our analyses of utility assumptions, we found that model results were highly sensitive to differences in treatment-state utilities. If the everyday quality-of-life experience of intensive glucose control was lower than that of moderate glucose control by more than 0.02 (a 2% reduction in daily quality of life from perfect health, 1.00 vs. 0.98), intensive control became a harmful therapy. Model results did not change significantly when we used lower utilities for complication states.
DISCUSSION
Our results show that limited life expectancy is an important determinant of the expected benefit of intensive glucose control compared with moderate glucose control, even among patients with long-standing diabetes. The results suggest that 5 years of life expectancy is an acceptable threshold for identifying older patients who are unlikely to benefit from intensive control. We found that patients with a life expectancy of 5 years or less would probably gain only 20 quality-adjusted days with intensive glucose control.
If life expectancy is important, then practical approaches to identifying older diabetic patients with limited life expectancy are needed. We found that a combination of multiple comorbid illnesses and functional impairments is a more important predictor of limited life expectancy and diminishing benefits of intensive glucose control than age alone. For patients 60 to 64 years of age, a combination of 4 long-standing comorbid illnesses or functional impairments is associated with a total mortality index score of 8 to 10, a life expectancy of less than 5 years, and significantly reduced benefits of 8 to 13 quality-adjusted days from intensive glucose control. On average, life expectancy is less than 5 years for patients age 60 to 64 years with 7 additional index points, patients age 65 to 69 years with 6 additional points, patients age 70 to 74 years with 5 additional points, and patients age 75 to 79 years with 4 additional points. In our analyses, we assumed that comorbid illnesses or functional impairments were permanent; however, these characteristics are actually dynamic (52) , which suggests that decisions about the intensity of glucose control need to be routinely revisited. Although these analyses provide insight into how the benefits of intensive glucose control may vary by clinical characteristics, they should not be the sole consideration when determining the goals of diabetes care for an individual patient. The mortality index we used was developed and validated at a population level, and our model's estimates represent the average effects for subgroups of patients; an individual patient's experiences may still vary from these average effects. In addition, concerns about the adverse consequences of pursuing intensive glucose control may be particularly relevant when identifying glucose control targets for some older patients (11, 53, 54) . The potential harms of pursuing near-normal glucose levels (target HbA 1c level Ͻ6.0%) in older patients are uncertain. The glucose control portion of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial was recently terminated because of excessive deaths in the very intensive glucose control group (55); however, the ADVANCE (Action in Diabetes and Vascular Disease) study has not reported excessive deaths attributable to very intensive glucose control (56). Other clinical trials that studied maintaining HbA 1c levels in the range of 7.0% have not documented similar harms to those observed in the AC-CORD trial (3); however, subgroups of older patients are probably at high risk for hypoglycemia and geriatric syndromes even with this traditional glucose control target. The uncertainty related to pursuing near-normal glucose levels underscores the importance of carefully tailoring diabetes care goals and plans to individual older patients on the basis of expected benefits and harms of therapy. A critical piece of this process is the acknowledgment of patients' treatment preferences, which should be important determinants of treatment decisions (45, 53) . The validity of our findings depends on the quality of our decision analytic model. We attempted to enhance the validity of our analyses by using the most up-to-date prediction models from both diabetes and geriatrics. In addition, our results have face validity in comparisons with expectations from epidemiologic studies of diabetes and related complications (51) . Our results regarding life ex- 
Level of Comorbid Illness or Functional Impairment
Level of comorbid illness or functional impairment is indicated by additional points on the mortality index score (1 to 2 points per illness or impairment). The relationships between absolute risk reductions for specific events and the mortality index score are not consistently monotonic because we assessed fairly wide ranges of duration of diabetes (5 years) and the individual complication models vary in their responsiveness to this variable. Expected differences for patients age 65 to 69 years and 70 to 74 years are intermediate to those of the subgroups presented here (Appendix Figure 2, No clinical trial data were directly available for older patients and patients with comorbid illnesses or functional impairment. Without such data, we relied on prediction models for diabetic complications that were developed from UKPDS trial results. Our findings are therefore specific to these prediction models and their study populations. In addition, we made several assumptions in our analysis, such as not accounting for the adverse consequences of intensive control, that biased the analysis favorably toward intensive control. Despite this bias, our analysis indicates a steady decline of expected benefits with an increasing mortality index score.
Our results provide support for the recommendations of geriatric diabetes care guidelines. The challenge for older patients and their providers is in deciding how best to apply results from clinical trials to the care of an individual. In the absence of directly applicable trial data, such methods as decision analysis allow us to integrate data from existing clinical trials with advancing knowledge about the health experiences of older diabetic patients and provide insight into the care of individuals. These personalized estimates provide a starting point for discussions between older diabetic patients and their providers about the value of pursuing a complex therapy, such as intensive glucose control.
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